Compare Ally Financial Inc (ALLY) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ally Financial Inc vs TG Therapeutics Inc — how do they compare? Ally Financial Inc trades at $43.92 (market cap $13.37B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Ally Financial Inc is the larger of the two by market cap, and Ally Financial Inc pays a 2.73% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ALLY | TGTX | |
|---|---|---|
Market Cap | $13.37B | $7.64B |
Sector | Financials | Health |
52-Week High | $47.25 | $59.06 |
52-Week Low | $35.96 | $26.94 |
Dividend Yield | 2.73% | — |
Enterprise Value | — | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ally Financial (ALLY) trades at $44.14, up 0.8% on the day, with a bearish technical signal but strong analyst support. The stock shows mixed earnings, beating estimates in Q1 2026 but missing in Q2, while maintaining a P/E of 10.34 and P/B of 0.99, indicating potential undervaluation. Recent news includes insider sales and corporate recognitions, alongside a declared $0.30 dividend payable in August 2026.
The outlook for ALLY is cautiously optimistic, with a consensus price target of $54.40 offering ~23% upside, though risks from higher provisions and macroeconomic pressures persist. Investment appeal lies in its low valuation and dividend, but investors must weigh credit risks and interest rate sensitivity against growth in auto finance and digital banking strengths.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ally Financial Inc
Ally Financial Inc is a diversified financial services firm that services automotive dealers and their retail customers. The company operates as a financial holding company and a bank holding company. Its banking subsidiary, Ally Bank, caters to the direct banking market through Internet, mobile, and mail. The company reports four business segments including Automotive Finance operations, Insurance operations, Mortgage Finance operations and Corporate Finance operations.
Read more on ALLY →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
